Daniel Arber to Myelodysplastic Syndromes
This is a "connection" page, showing publications Daniel Arber has written about Myelodysplastic Syndromes.
Connection Strength
6.472
-
Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia. Am J Hematol. 2023 03; 98(3):377-378.
Score: 0.695
-
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
Score: 0.599
-
Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? Best Pract Res Clin Haematol. 2020 06; 33(2):101139.
Score: 0.564
-
Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol. 2016 09; 29(9):996-1003.
Score: 0.441
-
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 05 19; 127(20):2391-405.
Score: 0.436
-
Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology Am Soc Hematol Educ Program. 2015; 2015:294-8.
Score: 0.399
-
Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. Am J Clin Pathol. 2014 Aug; 142(2):190-5.
Score: 0.388
-
E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol. 2014 May; 141(5):656-64.
Score: 0.381
-
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009 Feb 26; 113(9):1906-8.
Score: 0.264
-
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204(4):1243-1248.
Score: 0.186
-
Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. Hum Pathol. 2003 Aug; 34(8):809-13.
Score: 0.181
-
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. Leuk Res. 2023 07; 130:107309.
Score: 0.178
-
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023 04; 98(4):E76-E79.
Score: 0.175
-
EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Arch. 2022 Oct; 481(4):621-646.
Score: 0.168
-
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
Score: 0.166
-
Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. Am J Clin Pathol. 2002 Feb; 117(2):306-13.
Score: 0.163
-
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. 2020 08; 60(8):1867-1872.
Score: 0.146
-
Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol. 2017 Jul 01; 148(1):49-57.
Score: 0.119
-
Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol. 1997 Apr; 107(4):430-7.
Score: 0.117
-
Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017 03; 30(3):382-392.
Score: 0.114
-
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
Score: 0.094
-
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9.
Score: 0.094
-
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013 Feb 19; 110(8):3011-6.
Score: 0.088
-
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol. 2009 Jun; 146(1):86-90.
Score: 0.067
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51.
Score: 0.067
-
Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. Leukemia. 2002 Apr; 16(4):623-31.
Score: 0.041
-
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000 Mar 01; 95(5):1588-93.
Score: 0.036
-
Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Am J Clin Pathol. 1999 Mar; 111(3):373-8.
Score: 0.033
-
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 08; 102(8):1352-1360.
Score: 0.029
-
Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience. Am J Clin Pathol. 2013 Jun; 139(6):818-25.
Score: 0.022
-
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010 Aug; 85(8):600-6.
Score: 0.018